K23AI080842/AI/NIAID NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2009	1
2010	1
2011	2
2012	5
2013	3
2014	7
2015	4
2016	1
2021	0

1

Pipeline of drugs for related diseases: tuberculosis.

Dooley KE, Nuermberger EL, Diacon AH. Dooley KE, et al. Curr Opin HIV AIDS. 2013 Nov;8(6):579-85. doi: 10.1097/COH.0000000000000009. Curr Opin HIV AIDS. 2013. PMID: 24100880 Free PMC article. Review.

2

Tuberculosis and diabetes mellitus: convergence of two epidemics.

Dooley KE, Chaisson RE. Dooley KE, et al. Lancet Infect Dis. 2009 Dec;9(12):737-46. doi: 10.1016/S1473-3099(09)70282-8. Lancet Infect Dis. 2009. PMID: 19926034 Free PMC article. Review.

3

Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.

Dooley KE, Mitnick CD, Ann DeGroote M, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E; Efficacy Subgroup, RESIST-TB. Dooley KE, et al. Clin Infect Dis. 2012 Aug;55(4):572-81. doi: 10.1093/cid/cis487. Epub 2012 May 21. Clin Infect Dis. 2012. PMID: 22615332 Free PMC article. Review.

4

TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Matteelli A, Carvalho AC, Dooley KE, Kritski A. Matteelli A, et al. Future Microbiol. 2010 Jun;5(6):849-58. doi: 10.2217/fmb.10.50. Future Microbiol. 2010. PMID: 20521931 Free PMC article. Review.

5

World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL; Efficacy Subgroup, RESIST-TB. Dooley KE, et al. J Infect Dis. 2013 May 1;207(9):1352-8. doi: 10.1093/infdis/jis460. Epub 2012 Jul 17. J Infect Dis. 2013. PMID: 22807518 Free PMC article. Review.

6

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.

Svensson EM, Murray S, Karlsson MO, Dooley KE. Svensson EM, et al. J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504. Epub 2014 Dec 21. J Antimicrob Chemother. 2015. PMID: 25535219 Free PMC article. Clinical Trial.

7

Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H; TSHEPISO Study Team. Dooley KE, et al. J Infect Dis. 2015 Jan 15;211(2):197-205. doi: 10.1093/infdis/jiu429. Epub 2014 Jul 31. J Infect Dis. 2015. PMID: 25081933 Free PMC article.

8

Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.

Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H, Dooley KE. Denti P, et al. Antimicrob Agents Chemother. 2015 Dec 7;60(3):1234-41. doi: 10.1128/AAC.02051-15. Antimicrob Agents Chemother. 2015. PMID: 26643345 Free PMC article.

9

Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.

Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Savic RM, et al. Antimicrob Agents Chemother. 2014 Jun;58(6):3035-42. doi: 10.1128/AAC.01918-13. Epub 2014 Mar 10. Antimicrob Agents Chemother. 2014. PMID: 24614383 Free PMC article. Clinical Trial.

10

Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.

Svensson EM, Dooley KE, Karlsson MO. Svensson EM, et al. Antimicrob Agents Chemother. 2014 Nov;58(11):6406-12. doi: 10.1128/AAC.03246-14. Epub 2014 Aug 11. Antimicrob Agents Chemother. 2014. PMID: 25114140 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results